FDA May Ease Up On CV Safety Requirements For GI Motility Drugs Compared To Diabetes, Obesity

Developers of 5-HT4 agonists should not be required to conduct dedicated cardiovascular studies, despite the safety concerns raised by two previously approved products in the class, an FDA advisory committee said.